Antimicrobial therapy of bovine respiratory disease.
Our challenge in therapy of BRD is the selection of the appropriate therapy from antimicrobials with long-standing histories and newer compounds. The proliferation of new antimicrobials for BRD makes it difficult to justify the extralabel use of nonlabeled compounds. Evaluation of the BRD case definition and treatment population should be the first steps in selecting therapy and evaluating incidences of poor response.
Apley
M
M
Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, USA.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D018942:Macrolides; D010325:Pasteurella / Q000302:isolation & purification; D010326:Pasteurella Infections / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary; D010406:Penicillins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012137:Respiratory System / Q000382:microbiology / Q000473:pathology; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000382:microbiology / Q000662:veterinary*; D013754:Tetracyclines
D000900:Anti-Bacterial Agents; D018942:Macrolides; D010406:Penicillins; D013754:Tetracyclines